aibio
Listings ·
Reviva asks stockholders to approve reverse split of up to 1-for-100
The proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all.
RVPH Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings (RVPH) news RVPH reverse split and offering news
Latest Reviva Pharmaceuticals Holdings news
- Financings
Reviva Pharmaceuticals sets up $50 million at-the-market stock program
B. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025.
- Distress
Reviva Pharmaceuticals delays 2024 annual report and expects to report material weaknesses
The company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension.
What Reviva Pharmaceuticals Holdings does
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases with significant unmet medical needs. Its pipeline focuses on central nervous system, inflammatory and cardiometabolic diseases, and it uses a chemical genomics driven technology platform and proprietary chemistry. The company has two drug candidates, brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house. Its lead candidate, brilaroxazine, is in clinical development for schizophrenia, bipolar disorder, major depressive disorder, ADHD, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. The company says brilaroxazine is also ready for clinical development for pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and is in preclinical development for psoriasis. Its primary focus is completing clinical development of brilaroxazine for acute and maintenance schizophrenia. Recent developments include a one-for-twenty reverse stock split effective March 9, 2026, and a March 2026 public offering with net proceeds of approximately $8.9 million.
| Product or program | What it is | Stage |
|---|---|---|
| Brilaroxazine (RP5063) | Multimodal serotonin, dopamine and nicotinic receptor modulator for neuropsychiatric indications | in clinical development |
| RP1208 | New chemical entity discovered in-house with composition of matter patents |
Reviva Pharmaceuticals Holdings annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.7 million | $22.9 million |
| Net income (loss) | -$19.9 million | -$29.9 million |
| Cash from operations | -$24.6 million | -$33.5 million |
| Cash and equivalents | $14.4 million | $13.5 million |
Questions about Reviva Pharmaceuticals Holdings
Did Reviva Pharmaceuticals Holdings do a reverse stock split?
Our latest story on this, dated Oct 29, 2026: "Reviva asks stockholders to approve reverse split of up to 1-for-100". The story links the filing or release it is based on. Read the story.
Has Reviva Pharmaceuticals Holdings raised money recently?
Our latest story on this, dated May 30, 2025: "Reviva Pharmaceuticals sets up $50 million at-the-market stock program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Reviva Pharmaceuticals Holdings?
Reviva Pharmaceuticals Holdings, Inc. trades under the ticker RVPH on OTC.
Where is Reviva Pharmaceuticals Holdings listed?
Reviva Pharmaceuticals Holdings, Inc. is listed on OTC.
What is the SEC CIK of Reviva Pharmaceuticals Holdings?
The SEC Central Index Key (CIK) for Reviva Pharmaceuticals Holdings, Inc. is 1742927. Its filings are on SEC EDGAR.
How many shares does Reviva Pharmaceuticals Holdings have outstanding?
13,110,377 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Reviva Pharmaceuticals Holdings listed under?
Our directory records Reviva Pharmaceuticals Holdings, Inc. under United States.
What does Reviva Pharmaceuticals Holdings do?
Our directory classifies Reviva Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Reviva Pharmaceuticals Holdings?
The ISIN recorded for Reviva Pharmaceuticals Holdings, Inc. is US76152G2093.
Does aibio.space cover Reviva Pharmaceuticals Holdings?
aibio.space lists Reviva Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Reviva Pharmaceuticals Holdings incorporated?
SEC records list its state or country of incorporation as DE.
What does Reviva Pharmaceuticals Holdings develop?
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases with significant unmet medical needs. Its pipeline focuses on central nervous system, inflammatory and cardiometabolic diseases, and it uses a chemical genomics driven technology platform and proprietary chemistry.
What is Brilaroxazine (RP5063) from Reviva Pharmaceuticals Holdings?
Brilaroxazine (RP5063): Multimodal serotonin, dopamine and nicotinic receptor modulator for neuropsychiatric indications Stage: in clinical development.
What is RP1208 from Reviva Pharmaceuticals Holdings?
RP1208: New chemical entity discovered in-house with composition of matter patents Stage: not stated.
Is Reviva Pharmaceuticals Holdings profitable?
Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC.
Investor discussion: Reviva Pharmaceuticals Holdings
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,8.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Reviva Pharmaceuticals Holdings, Inc.
- CIK
- 1742927
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- RVPH (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 10080 N WOLFE ROAD, CUPERTINO, CA, 95014
- Phone
- 4085018881
- Shares outstanding
- 13,110,377 as of 2026-08-13 (10-Q filed 2026-08-12)
- Former names
- Tenzing Acquisition Corp.
Recent filings
Listing details
- Company
- Reviva Pharmaceuticals Holdings, Inc.
- Ticker
- RVPH
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US76152G2093
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction